Skip to main content

CHAIRS

Cheryl Ho, MD, FRCP(C)

Clinical Associate Professor
University of British Columbia
Medical Oncologist
British Columbia Cancer
Vancouver, BC

Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Randeep Sangha, MD, FRCPC

Associate Professor, University of Alberta
Medical Oncologist, Cross Cancer Institute
Director, Clinical Trials Unit, Cross Cancer Institute
Provincial Lead, Alberta Lung Cancer Program
Edmonton, AB

Randeep Sangha, MD, is an Associate Professor at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada.

Dr. Sangha obtained his medical degree from the University of Alberta Faculty of Medicine, where he also completed his his residency in Internal Medicine and Medical Oncology. He then pursued a post-training research fellowship at the University of California, Davis Comprehensive Cancer Center, focusing on thoracic malignancies.

Dr. Sangha is the Director of the Clinical Trials Unit at the Cross Cancer Institute. He also has been the Provincial Lead for the Alberta Lung Cancer Program. His clinical and research interests include treatment of thoracic and hematologic malignancies, as well as developmental and molecular therapeutics.

Devin Schellenberg, MD, FRCS(C)

Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto.  He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.

FACULTY

Felix JF Herth, MD, PhD, FCCP, FERS

Chairman and Head,
Dep. of Pneumology and Critical Care Medicine,
Thoraxklinik University of Heidelberg
Heidelberg, Germany

Professor Felix Herth, Thoraxklinik Heidelberg, Germany, graduated from the University of Freiburg, Germany, in 1990. He has been Head of the Department of Internal Medicine, Pulmonology and Critical Care Medicine at Thoraxklinik, Heidelberg, since 2004, and CEO and CMO of Thoraxklinik, University of Heidelberg, Heidelberg, since 2015.

His research interests include interventional pneumology, end-stage COPD and phenotyping of COPD. His group at Thoraxklinik is one of the world’s leading centers for the development of new minimal invasive endoscopic techniques, and his team initiated several trials on phenotyping of COPD for endoscopic lung volume reduction.

Professor Herth is Editor-in-Chief of Respiration and has served on many major committees, including the European Respiratory Society (ERS), the American College of Chest Physicians (ACCP) and the German Society of Pneumology (DGP). He published more than 600 peer reviewed articles and several books. He has also received numerous awards, including a Research Awards from from ERS, CTS, ACCP and DGP.

Anand Swaminath MD FRCP(C)

Associate Professor, Department of Oncology, McMaster University
Scientist, Escarpment Cancer Research Institute
OARO Clinician Scientist and Radiation Oncologist
Juravinski Cancer Centre
Hamilton, ON

Dr. Swaminath is an Associate Professor, Clinician Scientist and Radiation Oncologist at the Juravinski Cancer Centre, McMaster University, Hamilton.

He received his medical degree from the University of Ottawa, finished residency training at McMaster University, and completed a clinical-research fellowship in image-guided radiotherapy/SBRT for lung and liver cancer at the Princess Margaret Cancer Centre.

His clinical and research interests are in the application of new technologies in radiation therapy, specifically SBRT for a wide variety of indications including lung, kidney, and liver cancer, both for symptom control and in the management of metastatic disease.

Dr. Swaminath is a PI or radiation lead on several local, national, and international trials evaluating SBRT in both the primary and metastatic setting. Some trial highlights include the lead on the Canadian LUSTRE randomized lung SBRT trial, and radiation lead on the CYTOSHRINK and RADSTER trials in kidney cancer, and ADVANCE trial for HCC. He has authored or co-authored more than 80 peer reviewed publications and book chapters, and has obtained several large-scale grants through CIHR and CCSRI for trials that both locally and nationally involve the evaluation of SBRT in the primary and metastatic setting.

Heather Wakelee, MD, FASCO

Professor of Medicine/ Chief- Division of Oncology,
Stanford University School of Medicine
Deputy Director,
Stanford Cancer Institute
Stanford, CA

Dr. Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. She is past President of the International Association for the Study of Lung Cancer (IASLC) and is a Fellow of the American Society of Clinical Oncology (FASCO). Dr. Wakelee graduated from Princeton University and Johns Hopkins University School of Medicine and has been at Stanford University since internship. As an experienced investigator, Dr. Wakelee has authored or co-authored more than 300 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials involving adjuvant therapy, immunotherapy (particularly use of immunotherapy in the perioperative settng for NSCLC), and anti-angiogenesis agents. Her research additionally is focused on many specific lung cancer subtypes defined by mutations in genes such as EGFR, ALK, ROS1, RET, BRAF, as well as broad translational efforts.